| Literature DB >> 28814913 |
Abdirashit Maripov1,2, Argen Mamazhakypov1,3, Meerim Sartmyrzaeva1,2, Almaz Akunov1,2, Kubatbek Muratali Uulu1,2, Melis Duishobaev1,2, Meerim Cholponbaeva1,2, Akylbek Sydykov1,3, Akpay Sarybaev1,2.
Abstract
BACKGROUND: Recent studies have reported that obstructive sleep apnea (OSA) patients present alterations in right ventricular (RV) structure and function. However, large randomized controlled trials evaluating the impact of OSA on the right ventricle are lacking.Entities:
Mesh:
Year: 2017 PMID: 28814913 PMCID: PMC5549475 DOI: 10.1155/2017/1587865
Source DB: PubMed Journal: Can Respir J ISSN: 1198-2241 Impact factor: 2.409
Figure 1Flow chart of the literature search and study selection.
Characteristics of the included studies. RVID: right ventricular basal diameter measured at end-diastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep apnea; ESS: Epworth Sleepiness Scale; PSG: polysomnography; AHI: apnea-hypopnea index; PAP: pulmonary artery pressure; N/A: not applicable.
| Study | Year of publication | Country | Number of participants | Mean (SD) age (years) | BMI (kg/m2) | OSA diagnosis (methods; criteria)/control group determination | Mean (SD) ESS score | Mean (SD) AHI | Mean (SD) PAP (mmHg) | RV remodeling and dysfunction measures |
|---|---|---|---|---|---|---|---|---|---|---|
| Hanly et al. [ | 1992 | Canada | 31 (OSA) | 50 (12.3) | 32.8 (7.2) | PSG; AHI < 5 events/h | N/A | 49 (25.5) | N/A | RVID, RVWT |
| 20 (control) | 48 (8.8) | 26.2 (3.2) | PSG; AHI ≥ 5 events/h | N/A | 2.7 (1.6) | N/A | ||||
|
| ||||||||||
| Guidry et al. [ | 2001 | USA | 90 (OSA) | 60 (9) | 32 (5) | PSG; RDI > 90th percentile | N/A | 42.0 (15.3) (RDI) | N/A | RV FAC, RVWT, RVID |
| 90 (control) | 61 (9) | 28 (4) | PSG; RDI < 50th percentile | N/A | 4.6 (2.6) (RDI) | N/A | ||||
|
| ||||||||||
| Verbraecken et al. [ | 2005 | Belgium | 43 (OSA) | 55 (11) | 31.6 (5.4) | PSG; AHI > 20 events/h | N/A | 42 (24) | N/A | RVID, RV MPI, RV S' |
| 40 (control) | 50 (16) | 26.4 (2.3) | ESS score = 0 (all) | N/A | N/A | N/A | ||||
|
| ||||||||||
| Dursunoğlu et al. [ | 2005 | Turkey | 11 (mild OSA) | 46.0 (5.6) | 30.4 (4.0) | PSG; AHI > 5–< 15 events/h | N/A | 25.3 (2.6) | N/A | RVWT, RVID, RV MPI |
| 18 (moderate-to-severe OSA) | 46.5 (4.9) | 30.6 (4) | PSG; AHI ≥ 15 events/h | N/A | 50.1 (11.6) | N/A | ||||
| 20 (control) | 43.5 (6) | 29.3 (2.4) | PSG; AHI < 5 events/h | N/A | 5.2 (2.8) | N/A | ||||
|
| ||||||||||
| Shivalkar et al. [ | 2006 | Belgium | 43 (OSA) | 55 (11) | 31.6 (5.4) | PSG; AHI ≥ 5 events/h | N/A | N/A | 32 (10) | RVID, RV MPI, RV S' |
| 40 (control) | 50 (16) | 26.4 (2.3) | ESS score = 0 (all) | N/A | N/A | 22 (8) | ||||
|
| ||||||||||
| Kasikcioglu et al. [ | 2007 | Turkey | 10 (OSA) | 42 (6) | 30.6 (3.2) | PSG: AHI > 30 events/h | N/A | 43.8 (11.7) | N/A | RVID, RV S' |
| 10 (control) | 45 (9) | 27.7 (2.6) | Healthy males | N/A | 2.1 (1.0) | N/A | ||||
|
| ||||||||||
| Romero-Corral et al. [ | 2007 | USA | 15 (mild OSA). | 59 (14) | 33 (6) | PSG; AHI > 5–< 14 events/h | N/A | 9.2 (2.9) | 33.6 (12.7) | RV MPI, RV FAC |
| 36 (moderate-to-severe OSA) | 63 (14) | 33 (5) | PSG; AHI ≥ 15 events/h | N/A | 34.9 (17.9) | 33.9 (8.4) | ||||
| 26 (control) | 55 (15) | 31 (6) | PSG; AHI < 5 events/h | N/A | 1.7 (1.4) | 34.0 (9.4) | ||||
|
| ||||||||||
| Otto et al. [ | 2007 | USA | 23 (OSA) | 45 (3) | 33.7 (0.8) | PSG; AHI ≥ 5 events/h | N/A | 50 (7) | N/A | RVID, RV S' |
| 18 (control) | 45 (2) | 32.3 (0.9) | PSG; AHI < 5 events/h | N/A | 2 (0.4) | N/A | ||||
|
| ||||||||||
| Tavil et al. [ | 2007 | Turkey | 20 (OSA) | 50 (7) | 30 (7) | PSG; AHI ≥ 5 events/h | N/A | 31 (29) | N/A | TAPSE, RV S', RV MPI |
| 21 (control) | 49 (5) | 29 (6) | PSG; AHI < 5 events/h | N/A | 2 (2) | N/A | ||||
|
| ||||||||||
| Bayram et al. [ | 2008 | Turkey | 28 (OSA) | 44.8 (10.5) | 29.7 (5.3) | PSG; AHI ≥ 15 events/h | N/A | 62.3 (21.6) | N/A | RVID, RV S', |
| 18 (control) | 41.9 (11.5) | 27.9 (2.7) | PSG; AHI < 5 events/h | N/A | 2.6 (0.8) | N/A | ||||
|
| ||||||||||
| Kepez et al. [ | 2009 | Turkey | 45 (mild-to-moderate OSA) | 48.8 (8.2) | 28.4 (3.4) | PSG; AHI > 5–< 30 events/h | N/A | 15.0 (13.0) | N/A | RVID, RV S' |
| 40 (severe OSA) | 48.6 (9.2) | 31.5 (4.9) | PSG; AHI ≥ 30 events/h | N/A | 46.0 (42.0) | N/A | ||||
| 30 (control) | 46.1 (8.7) | 27.7 (4.0) | Absence of symptoms of sleep-related disorders | N/A | N/A | N/A | ||||
|
| ||||||||||
| Tugcu et al. [ | 2009 | Turkey | 41 (OSA) | 56 (12) | 31.38 (4.97) | PSG; AHI ≥ 15 events/h, ESS score ≥ 10 | 19.37 (4.30) | 38.84 (21.80) | 28.20 (4.66) | RVWT, TAPSE, RV MPI, RV S' |
| 30 (control) | 54 (10) | 30.10 (3.65) | PSG; AHI < 5 events/h, ESS score < 10 | 2.60 (2.29) | 1.46 (0.68) | 24.73 (2.49) | ||||
|
| ||||||||||
| Tugcu et al. [ | 2010 | Turkey | 27 (OSA) | 54 (10) | 31.1 (5.1) | PSG; AHI ≥ 15 events/h, ESS score ≥ 10 | N/A | 40 (22) | 26.6 (3.1) | RVWT, RVID, TAPSE, RV S' |
| 26 (control) | 54 (10) | 29.6 (3.6) | PSG; AHI < 5 events/h, ESS score < 10 | N/A | 2 (1) | 24.1 (2.3) | ||||
|
| ||||||||||
| Yang et al. [ | 2012 | China | 77 (mild OSA) | 58.4 (0.7) | 27.39 (5.74) | PSG; AHI 5–15 events/h, SpO2 nadir 85–89% | N/A | 20 (5.6) | 28 (6) | RVID, RVWT, RV MPI, |
| 81 (moderate OSA) | PSG; AHI 15–30 events/h, SpO2 nadir 80–84% | N/A | 38 (6) | |||||||
| 62 (severe OSA) | PSG; AHI > 30 events/h, SpO2 nadir <80% | N/A | 55 (11) | |||||||
| 75 (control) | 59.8 (1.1) | 26.32 (4.57) | PSG; AHI < 5 events/h | N/A | 2.9 (2) | 22 (5) | ||||
|
| ||||||||||
| Altekin et al. [ | 2012 | Turkey | 20 (mild OSA) | 46.95 (6.4) | 28.68 (3.44) | PSG; AHI > 5–< 15 events/h | N/A | 10.73 (2.57) | 27.62 (4.32) | RV MPI, TAPSE |
| 19 (moderate OSA) | 46.79 (5) | 29.05 (2.26) | PSG; AHI > 15–< 30 events/h | N/A | 20.52 (2.60) | 29.78 (4.24) | ||||
| 19 (severe OSA) | 46.68 (7.6) | 29.80 (2.38) | PSG; AHI ≥ 30 events/h | N/A | 58.1 (16.27) | 32.06 (3.71) | ||||
| 21 (control) | 45.38 (4.5) | 26.35 (4.14) | ESS score < 10 | N/A | N/A | 25.61 (5.43) | ||||
|
| ||||||||||
| Hammerstingl et al. [ | 2012 | Germany | 154 (OSA) | 61.7 (12.4) | 31.1 (5.8) | PSG; AHI < 5 events/h | 10.4 (5.2) | 35.9 (28.4) | 22.0 (12.6) | TAPSE, RV MPI |
| 29 (control) | 55.7 (15.8) | 30.1 (5.5) | PSG; AHI ≥ 5 events/h | 7.9 (5.6) | 2.3 (1.3) | 17.3 (11.9) | ||||
|
| ||||||||||
| Öztuna et al. [ | 2013 | Turkey | 23 (OSA) | 53.6 (7.1) | 34.8 (7.8) | PSG; AHI ≥ 15 events/h | 9.17 (5.10) | N/A | 21.8 (5.9) | RV MPI |
| 23 (control) | 53.7 (6.5) | 25.8 (1.7) | ESS score < 10 | 0.26 (0.54) | N/A | 22.1 (4.4) | ||||
|
| ||||||||||
| Araz et al. [ | 2014 | Turkey | 67 (OSA) | 49.7 (12.7) | 34.6 (8.3) | PSG; AHI ≥ 5 events/h | 10 (4) | 52 (6) | 41.2 (12.9) | RVID |
| 31 (control) | 49.8 (10.9) | 29.5 (7.3) | PSG; AHI < 5 events/h | 3 (2) | 1.5 (1.4) | 25.3 (7.5) | ||||
|
| ||||||||||
| Vitarelli et al. [ | 2015 | Italy | 10 (mild OSA) | 47.9 (10.3) | 26.9 (5.8) | PSG; AHI > 5–< 15 events/h | N/A | 7.1 (1.9) | 25 (6) | TAPSE, RV MPI, RV FAC, RV S' |
| 8 (moderate OSA) | 47.6 (9.1) | 27.4 (5.5) | PSG; AHI > 15–< 30 events/h | N/A | 19.8 (2.7) | 35 (11) | ||||
| 19 (severe OSA) | 48.1 (10.2) | 28.2 (6.3) | PSG; AHI ≥ 30 events/h | N/A | 58.9 (9.1) | 46 (11) | ||||
| 30 (control) | 46.2 (13.4) | 26.4 (4.3) | PSG; AHI < 5 events/h | N/A | 3.8 (1.4) | 22 (3) | ||||
|
| ||||||||||
| Ozkececi et al. [ | 2016 | Turkey | 30 (OSA) | 49.6 (11.7) | 31.6 (5.8) | PSG;AHI ≥ 5 events/h | N/A | 24.5 (6–98) | 22.4 (8.9) | RVID, RV MPI, RV S', TAPSE |
| 60 (control) | 46.4 (14) | 29.3 (4.8) | PSG; AHI < 5 events/h | N/A | 1 (1–4) | 12.7 (7.5) | ||||
|
| ||||||||||
| Altiparmak et al. [ | 2016 | Turkey | 52 (OSA) | 49 (10) | 26.5 (2.1) | PSG; AHI ≥ 5 events/h | N/A | N/A | 32.4 (7) | RVID, RVWT, TAPSE, RV S' |
| 42 (control) | 46(7) | 25.8(3.3) | PSG; AHI < 5 events/h | N/A | N/A | 21.6 (4.3) | ||||
|
| ||||||||||
| Li et al. [ | 2016 | China | 24 (mild OSA) | 47.3 (6.1) | 26.40 (3.12) | PSG; AHI > 5–< 15 events/h | N/A | 12.72 (2.03) | N/A | RVWT, RVID, TAPSE, RV FAC |
| 25 (moderate OSA) | 47.9 (7.9) | 26.83 (3.55) | PSG; AHI > 15–< 30 events/h | N/A | 24.01 (3.56) | N/A | ||||
| 20 (severe OSA) | 48.5 (5.4) | 27.97 (3.59) | PSG; AHI ≥ 30 events/h | N/A | 40.78 (5.02) | N/A | ||||
| 31 (control) | 46.8 (5.4) | 24.86 (2.78) | PSG; AHI < 5 events/h | N/A | 1.72 (1.01) | N/A | ||||
|
| ||||||||||
| Dobrowolski et al. [ | 2016 | Poland | 45 (mild OSA) | 47.5 (10.5) All | N/A | PSG; AHI > 5–< 15 events/h | N/A | N/A | N/A | TAPSE, RV FAC, RV S' |
| 27 (moderate OSA) | N/A | PSG; AHI > 15–< 30 events/h | N/A | N/A | N/A | |||||
| 40 (severe OSA) | N/A | PSG; AHI ≥ 30 events/h | N/A | N/A | N/A | |||||
| 43 (control) | N/A | PSG; AHI < 5 events/h | N/A | N/A | N/A | |||||
|
| ||||||||||
| Zhou et al. [ | 2016 | China | 21 (mild OSA) | 52.8 (11.9) | 29.6 (9.1) | PSG; AHI > 5–< 15 events/h | N/A | N/A | 35.7 (6.1) | RV FAC, RV MPI |
| 19 (moderate OSA) | 55.7 (12.4) | 35.2 (10.1) | PSG; AHI > 15–< 30 events/h | N/A | N/A | 33.4 (5.8) | ||||
| 23 (severe OSA) | 50.2 (12.1) | 39.2 (9.8) | PSG; AHI ≥ 30 events/h | N/A | N/A | 18.7 (6.9) | ||||
| 19 (control) | 52.0 (10.8) | 24.2 (3.7) | PSG; AHI < 5 events/h | N/A | N/A | 16.7 (6.2) | ||||
|
| ||||||||||
| D'Andrea et al. [ | 2016 | Italy | 55 (OSA) | 67.8 (11.2) | 33.6 (6.6) | PSG; AHI ≥ 5 events/h | N/A | 35.1 (15.4) | 35.8 (14.4) | RVID, RVWT, TAPSE |
| 45 (control) | 65.9 (12.3) | 28.7 (3.6) | Absence of cardiovascular, structural, and functional abnormalities | N/A | N/A | 24.8 (11.3) | ||||
Figure 2Forest plot of the differences in right ventricular internal diameter (RVID) at diastole between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Figure 3Forest plot of the differences in right ventricular free wall thickness (RVWT) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Figure 4Forest plot of the differences in right ventricular myocardial performance index (RV MPI) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Figure 5Forest plot of the differences in right ventricular annular systolic velocity (RV S') between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Figure 6Forest plot of the differences in tricuspid annular plane systolic excursion (TAPSE) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Figure 7Forest plot of the differences in right ventricular fractional change (RV FAC) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
Results of the meta-analysis comparing OSA patients and healthy controls. RVID: right ventricular basal diameter measured at end-diastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.
| Echocardiographic parameters | Number of studies | OSA/control | WMD (95% CI) |
| Study heterogeneity | Egger's test | ||
|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||
| RVID | 16 | 902/596 | 2.49 (1.62, 3.37) | 0.000 | 96.8% | 647.61 | 0.000 | 0.001 |
| RVWT | 9 | 579/397 | 0.82 (0.51, 1.13) | 0.000 | 95.6% | 344.56 | 0.000 | 0.671 |
| RV MPI | 14 | 864/434 | 0.08 (0.06, 0.10) | 0.000 | 84.1% | 157.39 | 0.000 | 0.150 |
| RV S' | 14 | 639/391 | −0.95 (−1.59, −0.32) | 0.003 | 88.4% | 190.21 | 0.000 | 0.347 |
| TAPSE | 11 | 655/378 | −1.76 (−2.73, −0.78) | 0.000 | 89.3% | 187.24 | 0.000 | 0.462 |
| RV FAC | 6 | 422/239 | −3.16 (−5.60, −0.73) | 0.011 | 80.2% | 70.83 | 0.000 | 0.006 |